Blueprint Medicines Q3 2023 Earnings Report

Blueprint Medicines EPS Results

• Actual EPS: -$2.20
• Consensus EPS: -$2.39
• Beat/Miss: Beat by +$0.19
• One Year Ago EPS: -$2.23

Blueprint Medicines Revenue Results

• Actual Revenue: $56.57 million
• Expected Revenue: $50.66 million
• Beat/Miss: Beat by +$5.91 million
• YoY Revenue Growth: -14.30%

Blueprint Medicines Announcement Details

• Quarter: Q3 2023
• Date: 10/26/2023
• Time: Before Market Opens

Blueprint Medicines (NASDAQ:BPMC), a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.